Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan-Dou-Fu-Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model
Background: Gan-Dou-Fu-Mu decoction (GDFMD) improves liver fibrosis in experimental and clinical studies including those on toxic mouse model of Wilson disease (Model). However, the mechanisms underlying the effect of GDFMD have not been characterized. Herein, we deciphered the potential therapeutic...
Gespeichert in:
Veröffentlicht in: | Frontiers in pharmacology 2021-04, Vol.12, p.622268-622268, Article 622268 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 622268 |
---|---|
container_issue | |
container_start_page | 622268 |
container_title | Frontiers in pharmacology |
container_volume | 12 |
creator | Wei, Taohua Hao, Wenjie Tang, Lulu Wu, Huan Huang, Shi Yang, Yue Qian, Nannan Liu, Jie Yang, Wenming Duan, Xianchun |
description | Background: Gan-Dou-Fu-Mu decoction (GDFMD) improves liver fibrosis in experimental and clinical studies including those on toxic mouse model of Wilson disease (Model). However, the mechanisms underlying the effect of GDFMD have not been characterized. Herein, we deciphered the potential therapeutic targets of GDFMD using transcriptome analysis.
Methods: We constructed a tx-j Wilson disease (WD) mouse model, and assessed the effect of GDFMD on the liver of model mice by hematoxylin and eosin, Masson, and immunohistochemical staining. Subsequently, we identified differentially expressed genes (DEGs) that were upregulated in the Model (Model vs. control) and those that were downregulated upon GDFMD treatment (compared to the Model) using RNA-sequencing (RNA-Seq). Biological functions and signaling pathways in which the DEGs were involved were determined by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses. A protein-protein interaction (PPI) network was constructed using the STRING database, and the modules were identified using MCODE plugin with the Cytoscape software. Several genes identified in the RNA-Seq analysis were validated by real-time quantitative PCR.
Results: Total of 2124 DEGs were screened through the Model vs. control and Model vs. GDFMD comparisons, and dozens of GO and KEGG pathway terms modulated by GDFMD were identified. Dozens of pathways involved in metabolism (including metabolic processes for organic acids, carboxylic acids, monocarboxylic acids, lipids, fatty acids, cellular lipids, steroids, alcohols, eicosanoids, long-chain fatty acids), immune and inflammatory response (such as complement and coagulation cascades, cytokine-cytokine receptor interaction, inflammatory mediator regulation of TRP channels, antigen processing and presentation, T-cell receptor signaling pathway), liver fibrosis (such as ECM-receptor interactions), and cell death (PI3K-Akt signaling pathway, apoptosis, TGF-beta signaling pathway, etc.) were identified as potential targets of GDFMD in the Model. Some hub genes and four modules were identified in the PPI network. The results of real-time quantitative PCR analysis were consistent with those of RNA-Seq analysis.
Conclusions: We performed gene expression profiling of GDFMD-treated WD model mice using RNA-Seq analysis and found the genes, pathways, and processes effected by the treatment. Our study provides a theoretical basis to prevent liver fibrosis resulting from WD usi |
doi_str_mv | 10.3389/fphar.2021.622268 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8082393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_caf30989ca9644cfbcf51b13f343ed2c</doaj_id><sourcerecordid>2521501344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-acbd9024930c5581d02987428091bab526646271f7bb1bfb622dd3fe3f058dad3</originalsourceid><addsrcrecordid>eNqNUk1vEzEQXSEQrUp_ABfkIxLa4K917AtSlNBSqQEEqThaXu84cdmsU3u30J_Sf1snKVF7wz7Ymnnv2TPziuItwSPGpProNisTRxRTMhKUUiFfFMdECFYqSejLJ_ej4jSla5wXU4oJ_ro4Ykyxakyq4-J-GtabCCvokr8F9OPrpPwJN2jSmfYu-YSCQ99DD13vTYsWK4hmA0PvLVqYuIR-Bzg3XTkLQ3k2lPMBzcAG2_vQIRciWkQw_Trzt8Bfvk05PvMJTAJ0lXy3RAYtwt8sOPftbzQPQ07MQwPtm-KVM22C08fzpLg6-7yYfikvv51fTCeXpeWi6ktj60ZhyhXDtqokaTBVcsypxIrUpq6oEFzQMXHjuia1q3OvmoY5YA5XsjENOyku9rpNMNd6E_3axDsdjNe7QIhLbWKuuAVtjWNYSWWNEpxbV1tXkZowxziDhtqs9WmvtRnqNTQ21x1N-0z0eabzK70Mt1piSfNMssD7R4EYbgZIvV77ZKFtTQe5NZpWlFSYMM4zlOyhNoaUIrjDMwTrrUP0ziF66xC9d0jmvHv6vwPjnx8yQO4Bf6AOLlkPnYUDLFtI8CpvtXUTmfrebAc9DUPXZ-qH_6eyB2zR2pU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2521501344</pqid></control><display><type>article</type><title>Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan-Dou-Fu-Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wei, Taohua ; Hao, Wenjie ; Tang, Lulu ; Wu, Huan ; Huang, Shi ; Yang, Yue ; Qian, Nannan ; Liu, Jie ; Yang, Wenming ; Duan, Xianchun</creator><creatorcontrib>Wei, Taohua ; Hao, Wenjie ; Tang, Lulu ; Wu, Huan ; Huang, Shi ; Yang, Yue ; Qian, Nannan ; Liu, Jie ; Yang, Wenming ; Duan, Xianchun</creatorcontrib><description>Background: Gan-Dou-Fu-Mu decoction (GDFMD) improves liver fibrosis in experimental and clinical studies including those on toxic mouse model of Wilson disease (Model). However, the mechanisms underlying the effect of GDFMD have not been characterized. Herein, we deciphered the potential therapeutic targets of GDFMD using transcriptome analysis.
Methods: We constructed a tx-j Wilson disease (WD) mouse model, and assessed the effect of GDFMD on the liver of model mice by hematoxylin and eosin, Masson, and immunohistochemical staining. Subsequently, we identified differentially expressed genes (DEGs) that were upregulated in the Model (Model vs. control) and those that were downregulated upon GDFMD treatment (compared to the Model) using RNA-sequencing (RNA-Seq). Biological functions and signaling pathways in which the DEGs were involved were determined by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses. A protein-protein interaction (PPI) network was constructed using the STRING database, and the modules were identified using MCODE plugin with the Cytoscape software. Several genes identified in the RNA-Seq analysis were validated by real-time quantitative PCR.
Results: Total of 2124 DEGs were screened through the Model vs. control and Model vs. GDFMD comparisons, and dozens of GO and KEGG pathway terms modulated by GDFMD were identified. Dozens of pathways involved in metabolism (including metabolic processes for organic acids, carboxylic acids, monocarboxylic acids, lipids, fatty acids, cellular lipids, steroids, alcohols, eicosanoids, long-chain fatty acids), immune and inflammatory response (such as complement and coagulation cascades, cytokine-cytokine receptor interaction, inflammatory mediator regulation of TRP channels, antigen processing and presentation, T-cell receptor signaling pathway), liver fibrosis (such as ECM-receptor interactions), and cell death (PI3K-Akt signaling pathway, apoptosis, TGF-beta signaling pathway, etc.) were identified as potential targets of GDFMD in the Model. Some hub genes and four modules were identified in the PPI network. The results of real-time quantitative PCR analysis were consistent with those of RNA-Seq analysis.
Conclusions: We performed gene expression profiling of GDFMD-treated WD model mice using RNA-Seq analysis and found the genes, pathways, and processes effected by the treatment. Our study provides a theoretical basis to prevent liver fibrosis resulting from WD using GDFMD.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2021.622268</identifier><identifier>PMID: 33935715</identifier><language>eng</language><publisher>LAUSANNE: Frontiers Media Sa</publisher><subject>Gan–Dou–Fu–Mu decoction (GDFMD) ; Life Sciences & Biomedicine ; Pharmacology ; Pharmacology & Pharmacy ; RNA-sequencing ; Science & Technology ; toxic milk mice (TX mice) ; traditional Chinese medicine (TCM) ; Wilson disease (WD)</subject><ispartof>Frontiers in pharmacology, 2021-04, Vol.12, p.622268-622268, Article 622268</ispartof><rights>Copyright © 2021 Wei, Hao, Tang, Wu, Huang, Yang, Qian, Liu, Yang and Duan.</rights><rights>Copyright © 2021 Wei, Hao, Tang, Wu, Huang, Yang, Qian, Liu, Yang and Duan. 2021 Wei, Hao, Tang, Wu, Huang, Yang, Qian, Liu, Yang and Duan</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000645454900001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c465t-acbd9024930c5581d02987428091bab526646271f7bb1bfb622dd3fe3f058dad3</citedby><cites>FETCH-LOGICAL-c465t-acbd9024930c5581d02987428091bab526646271f7bb1bfb622dd3fe3f058dad3</cites><orcidid>0000-0003-2752-8035</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082393/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082393/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2106,2118,27933,27934,39267,53800,53802</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33935715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wei, Taohua</creatorcontrib><creatorcontrib>Hao, Wenjie</creatorcontrib><creatorcontrib>Tang, Lulu</creatorcontrib><creatorcontrib>Wu, Huan</creatorcontrib><creatorcontrib>Huang, Shi</creatorcontrib><creatorcontrib>Yang, Yue</creatorcontrib><creatorcontrib>Qian, Nannan</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Yang, Wenming</creatorcontrib><creatorcontrib>Duan, Xianchun</creatorcontrib><title>Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan-Dou-Fu-Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model</title><title>Frontiers in pharmacology</title><addtitle>FRONT PHARMACOL</addtitle><addtitle>Front Pharmacol</addtitle><description>Background: Gan-Dou-Fu-Mu decoction (GDFMD) improves liver fibrosis in experimental and clinical studies including those on toxic mouse model of Wilson disease (Model). However, the mechanisms underlying the effect of GDFMD have not been characterized. Herein, we deciphered the potential therapeutic targets of GDFMD using transcriptome analysis.
Methods: We constructed a tx-j Wilson disease (WD) mouse model, and assessed the effect of GDFMD on the liver of model mice by hematoxylin and eosin, Masson, and immunohistochemical staining. Subsequently, we identified differentially expressed genes (DEGs) that were upregulated in the Model (Model vs. control) and those that were downregulated upon GDFMD treatment (compared to the Model) using RNA-sequencing (RNA-Seq). Biological functions and signaling pathways in which the DEGs were involved were determined by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses. A protein-protein interaction (PPI) network was constructed using the STRING database, and the modules were identified using MCODE plugin with the Cytoscape software. Several genes identified in the RNA-Seq analysis were validated by real-time quantitative PCR.
Results: Total of 2124 DEGs were screened through the Model vs. control and Model vs. GDFMD comparisons, and dozens of GO and KEGG pathway terms modulated by GDFMD were identified. Dozens of pathways involved in metabolism (including metabolic processes for organic acids, carboxylic acids, monocarboxylic acids, lipids, fatty acids, cellular lipids, steroids, alcohols, eicosanoids, long-chain fatty acids), immune and inflammatory response (such as complement and coagulation cascades, cytokine-cytokine receptor interaction, inflammatory mediator regulation of TRP channels, antigen processing and presentation, T-cell receptor signaling pathway), liver fibrosis (such as ECM-receptor interactions), and cell death (PI3K-Akt signaling pathway, apoptosis, TGF-beta signaling pathway, etc.) were identified as potential targets of GDFMD in the Model. Some hub genes and four modules were identified in the PPI network. The results of real-time quantitative PCR analysis were consistent with those of RNA-Seq analysis.
Conclusions: We performed gene expression profiling of GDFMD-treated WD model mice using RNA-Seq analysis and found the genes, pathways, and processes effected by the treatment. Our study provides a theoretical basis to prevent liver fibrosis resulting from WD using GDFMD.</description><subject>Gan–Dou–Fu–Mu decoction (GDFMD)</subject><subject>Life Sciences & Biomedicine</subject><subject>Pharmacology</subject><subject>Pharmacology & Pharmacy</subject><subject>RNA-sequencing</subject><subject>Science & Technology</subject><subject>toxic milk mice (TX mice)</subject><subject>traditional Chinese medicine (TCM)</subject><subject>Wilson disease (WD)</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>DOA</sourceid><recordid>eNqNUk1vEzEQXSEQrUp_ABfkIxLa4K917AtSlNBSqQEEqThaXu84cdmsU3u30J_Sf1snKVF7wz7Ymnnv2TPziuItwSPGpProNisTRxRTMhKUUiFfFMdECFYqSejLJ_ej4jSla5wXU4oJ_ro4Ykyxakyq4-J-GtabCCvokr8F9OPrpPwJN2jSmfYu-YSCQ99DD13vTYsWK4hmA0PvLVqYuIR-Bzg3XTkLQ3k2lPMBzcAG2_vQIRciWkQw_Trzt8Bfvk05PvMJTAJ0lXy3RAYtwt8sOPftbzQPQ07MQwPtm-KVM22C08fzpLg6-7yYfikvv51fTCeXpeWi6ktj60ZhyhXDtqokaTBVcsypxIrUpq6oEFzQMXHjuia1q3OvmoY5YA5XsjENOyku9rpNMNd6E_3axDsdjNe7QIhLbWKuuAVtjWNYSWWNEpxbV1tXkZowxziDhtqs9WmvtRnqNTQ21x1N-0z0eabzK70Mt1piSfNMssD7R4EYbgZIvV77ZKFtTQe5NZpWlFSYMM4zlOyhNoaUIrjDMwTrrUP0ziF66xC9d0jmvHv6vwPjnx8yQO4Bf6AOLlkPnYUDLFtI8CpvtXUTmfrebAc9DUPXZ-qH_6eyB2zR2pU</recordid><startdate>20210415</startdate><enddate>20210415</enddate><creator>Wei, Taohua</creator><creator>Hao, Wenjie</creator><creator>Tang, Lulu</creator><creator>Wu, Huan</creator><creator>Huang, Shi</creator><creator>Yang, Yue</creator><creator>Qian, Nannan</creator><creator>Liu, Jie</creator><creator>Yang, Wenming</creator><creator>Duan, Xianchun</creator><general>Frontiers Media Sa</general><general>Frontiers Media S.A</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2752-8035</orcidid></search><sort><creationdate>20210415</creationdate><title>Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan-Dou-Fu-Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model</title><author>Wei, Taohua ; Hao, Wenjie ; Tang, Lulu ; Wu, Huan ; Huang, Shi ; Yang, Yue ; Qian, Nannan ; Liu, Jie ; Yang, Wenming ; Duan, Xianchun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-acbd9024930c5581d02987428091bab526646271f7bb1bfb622dd3fe3f058dad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Gan–Dou–Fu–Mu decoction (GDFMD)</topic><topic>Life Sciences & Biomedicine</topic><topic>Pharmacology</topic><topic>Pharmacology & Pharmacy</topic><topic>RNA-sequencing</topic><topic>Science & Technology</topic><topic>toxic milk mice (TX mice)</topic><topic>traditional Chinese medicine (TCM)</topic><topic>Wilson disease (WD)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wei, Taohua</creatorcontrib><creatorcontrib>Hao, Wenjie</creatorcontrib><creatorcontrib>Tang, Lulu</creatorcontrib><creatorcontrib>Wu, Huan</creatorcontrib><creatorcontrib>Huang, Shi</creatorcontrib><creatorcontrib>Yang, Yue</creatorcontrib><creatorcontrib>Qian, Nannan</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Yang, Wenming</creatorcontrib><creatorcontrib>Duan, Xianchun</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wei, Taohua</au><au>Hao, Wenjie</au><au>Tang, Lulu</au><au>Wu, Huan</au><au>Huang, Shi</au><au>Yang, Yue</au><au>Qian, Nannan</au><au>Liu, Jie</au><au>Yang, Wenming</au><au>Duan, Xianchun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan-Dou-Fu-Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model</atitle><jtitle>Frontiers in pharmacology</jtitle><stitle>FRONT PHARMACOL</stitle><addtitle>Front Pharmacol</addtitle><date>2021-04-15</date><risdate>2021</risdate><volume>12</volume><spage>622268</spage><epage>622268</epage><pages>622268-622268</pages><artnum>622268</artnum><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Background: Gan-Dou-Fu-Mu decoction (GDFMD) improves liver fibrosis in experimental and clinical studies including those on toxic mouse model of Wilson disease (Model). However, the mechanisms underlying the effect of GDFMD have not been characterized. Herein, we deciphered the potential therapeutic targets of GDFMD using transcriptome analysis.
Methods: We constructed a tx-j Wilson disease (WD) mouse model, and assessed the effect of GDFMD on the liver of model mice by hematoxylin and eosin, Masson, and immunohistochemical staining. Subsequently, we identified differentially expressed genes (DEGs) that were upregulated in the Model (Model vs. control) and those that were downregulated upon GDFMD treatment (compared to the Model) using RNA-sequencing (RNA-Seq). Biological functions and signaling pathways in which the DEGs were involved were determined by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses. A protein-protein interaction (PPI) network was constructed using the STRING database, and the modules were identified using MCODE plugin with the Cytoscape software. Several genes identified in the RNA-Seq analysis were validated by real-time quantitative PCR.
Results: Total of 2124 DEGs were screened through the Model vs. control and Model vs. GDFMD comparisons, and dozens of GO and KEGG pathway terms modulated by GDFMD were identified. Dozens of pathways involved in metabolism (including metabolic processes for organic acids, carboxylic acids, monocarboxylic acids, lipids, fatty acids, cellular lipids, steroids, alcohols, eicosanoids, long-chain fatty acids), immune and inflammatory response (such as complement and coagulation cascades, cytokine-cytokine receptor interaction, inflammatory mediator regulation of TRP channels, antigen processing and presentation, T-cell receptor signaling pathway), liver fibrosis (such as ECM-receptor interactions), and cell death (PI3K-Akt signaling pathway, apoptosis, TGF-beta signaling pathway, etc.) were identified as potential targets of GDFMD in the Model. Some hub genes and four modules were identified in the PPI network. The results of real-time quantitative PCR analysis were consistent with those of RNA-Seq analysis.
Conclusions: We performed gene expression profiling of GDFMD-treated WD model mice using RNA-Seq analysis and found the genes, pathways, and processes effected by the treatment. Our study provides a theoretical basis to prevent liver fibrosis resulting from WD using GDFMD.</abstract><cop>LAUSANNE</cop><pub>Frontiers Media Sa</pub><pmid>33935715</pmid><doi>10.3389/fphar.2021.622268</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-2752-8035</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1663-9812 |
ispartof | Frontiers in pharmacology, 2021-04, Vol.12, p.622268-622268, Article 622268 |
issn | 1663-9812 1663-9812 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8082393 |
source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Gan–Dou–Fu–Mu decoction (GDFMD) Life Sciences & Biomedicine Pharmacology Pharmacology & Pharmacy RNA-sequencing Science & Technology toxic milk mice (TX mice) traditional Chinese medicine (TCM) Wilson disease (WD) |
title | Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan-Dou-Fu-Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T06%3A54%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comprehensive%20RNA-Seq%20Analysis%20of%20Potential%20Therapeutic%20Targets%20of%20Gan-Dou-Fu-Mu%20Decoction%20for%20Treatment%20of%20Wilson%20Disease%20Using%20a%20Toxic%20Milk%20Mouse%20Model&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Wei,%20Taohua&rft.date=2021-04-15&rft.volume=12&rft.spage=622268&rft.epage=622268&rft.pages=622268-622268&rft.artnum=622268&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2021.622268&rft_dat=%3Cproquest_pubme%3E2521501344%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2521501344&rft_id=info:pmid/33935715&rft_doaj_id=oai_doaj_org_article_caf30989ca9644cfbcf51b13f343ed2c&rfr_iscdi=true |